Results 171 to 180 of about 25,818 (186)

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration

Nature Medicine, 2020
Alexander Drilon, Jeffrey W Clark, Benjamin J Solomon   +2 more
exaly  

Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy

Nature, 2014
Kilian Huber, Jonathan M Elkins, Alexey Stukalov   +2 more
exaly  

Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial

Lancet Respiratory Medicine,the, 2020
Jianya Zhou, Jianying Zhou, Yanqiu Zhao
exaly  

Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

Science Translational Medicine, 2012
Ryohei Katayama, Mari Mino-Kenudson, Benjamin J Solomon   +2 more
exaly  

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

Lancet Oncology, The, 2016
Gregory J Riely, Bo H Chao, Kathryn A Gold   +2 more
exaly  

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non–Small-Cell Lung Cancer

Journal of Clinical Oncology, 2018
Benjamin J Solomon, Dong-Wan Kim, Yi-Long Wu   +2 more
exaly  

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

Lancet Oncology, The, 2011
Benjamin J Solomon, Daniel B Costa, Sai-Hong I Ou   +2 more
exaly  

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study

Lancet Oncology, The, 2013
Keith D Wilner, Delphine Rolland, Frank Balis   +2 more
exaly  

Crizotinib-induced immunogenic cell death in non-small cell lung cancer

Nature Communications, 2019
Peng Liu, Liwei Zhao, Jonathan G Pol
exaly  

Crizotinib

Reactions Weekly, 2023
openaire   +1 more source